NASDAQ: APLMApollomics Inc Stock
$7.69-0.31 (-3.88%)
Updated Mar 14, 2025
APLM Price
$7.69
Fair Value Price
$0.12
Market Cap
$8.46M
52 Week Low
$6.20
52 Week High
$75.00
P/E
-0.51x
P/B
0.41x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$57.11M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.66
Operating Cash Flow
-$35M
Beta
-0.02
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
APLM Overview
Maxpro Capital Acquisition Corporation is a "blank check" company formed to effect mergers, stock purchases, or similar combinations with one or more businesses. It targets businesses in the financial services industry. Maxpro Capital Acquisition was incorporated in 2021 and is based in Taipei, Taiwan.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine APLM's potential to beat the market
- APLM doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
APLM
RankedUnranked of 484
RankedUnranked of 484
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.84 | A | |
| $137.96 | A | |
| $8.16 | A |
Be the first to know about important APLM news, forecast changes, insider trades & much more!
APLM News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how APLM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
APLM ($7.69) is overvalued by 6,141.15% relative to our estimate of its Fair Value price of $0.12 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
APLM ($7.69) is not significantly undervalued (6,141.15%) relative to our estimate of its Fair Value price of $0.12 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
APLM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more APLM due diligence checks available for Premium users.
Valuation
APLM fair value
Fair Value of APLM stock based on Discounted Cash Flow (DCF)
Price
$7.69
Fair Value
$0.12
Overvalued by
6,141.15%
APLM ($7.69) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
APLM ($7.69) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
APLM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
APLM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.51x
Industry
-118.09x
Market
3,446.57x
APLM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.41x
Industry
4.68x
APLM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
APLM's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
APLM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$34.6M
Liabilities
$13.8M
Debt to equity
0.66
APLM's short-term assets ($28.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
APLM's short-term assets ($28.41M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
APLM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
APLM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
APLM vs Biotech Stocks
Apollomics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.